Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Severine Vermeire

Showing results (11-20 of 232) with videos related to

Pageof 24
Sort By:
Expert Opinion on Drug Safety|December 6, 2017
Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel diseaseKaren van Hoeve, Ilse Hoffman, Severine Vermeire
F1000 Medicine Reports|December 21, 2010
Vaccination and infection prevention in inflammatory bowel diseaseSeverine Vermeire, Gert Van Assche, Paul Rutgeerts
Gut|March 21, 2007
Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?Paul Rutgeerts, Severine Vermeire, Gert Van Assche
Current Opinion in Gastroenterology|June 1, 2012
Classification of inflammatory bowel disease: the old and the newSeverine Vermeire, Gert Van Assche, Paul Rutgeerts
Expert Opinion on Medical Diagnostics|March 19, 2013
Role of biomarkers in the diagnosis of inflammatory bowel diseaseSeverine Vermeire, Gert Van Assche, Paul Rutgeerts
World Journal of Gastroenterology|June 15, 2006
Pharmacogenetics in inflammatory bowel diseaseMarie Pierik, Paul Rutgeerts, Robert Vlietinck, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 8, 2019
How, When, and for Whom Should We Perform Therapeutic Drug Monitoring?Severine Vermeire, Erwin Dreesen, Konstantinos Papamichael, et al.
Clinical Pharmacology and Therapeutics|October 4, 2005
The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipientsDirk R J Kuypers, Maarten Naesens, Severine Vermeire, et al.
Gastroenterology Clinics of North America|May 24, 2008
(Auto)antibodies in inflammatory bowel diseasesSeverine Vermeire, Nathalie Vermeulen, Gert Van Assche, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 26, 2010
Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severitySeverine Vermeire, Stefan Schreiber, William J Sandborn, et al.
Pageof 24

Showing results (11-20 of 232) with videos related to

Sort By:
Pageof 24
Expert Opinion on Drug Safety|December 6, 2017
Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel diseaseKaren van Hoeve, Ilse Hoffman, Severine Vermeire
F1000 Medicine Reports|December 21, 2010
Vaccination and infection prevention in inflammatory bowel diseaseSeverine Vermeire, Gert Van Assche, Paul Rutgeerts
Gut|March 21, 2007
Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?Paul Rutgeerts, Severine Vermeire, Gert Van Assche
Current Opinion in Gastroenterology|June 1, 2012
Classification of inflammatory bowel disease: the old and the newSeverine Vermeire, Gert Van Assche, Paul Rutgeerts
Expert Opinion on Medical Diagnostics|March 19, 2013
Role of biomarkers in the diagnosis of inflammatory bowel diseaseSeverine Vermeire, Gert Van Assche, Paul Rutgeerts
World Journal of Gastroenterology|June 15, 2006
Pharmacogenetics in inflammatory bowel diseaseMarie Pierik, Paul Rutgeerts, Robert Vlietinck, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 8, 2019
How, When, and for Whom Should We Perform Therapeutic Drug Monitoring?Severine Vermeire, Erwin Dreesen, Konstantinos Papamichael, et al.
Clinical Pharmacology and Therapeutics|October 4, 2005
The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipientsDirk R J Kuypers, Maarten Naesens, Severine Vermeire, et al.
Gastroenterology Clinics of North America|May 24, 2008
(Auto)antibodies in inflammatory bowel diseasesSeverine Vermeire, Nathalie Vermeulen, Gert Van Assche, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 26, 2010
Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severitySeverine Vermeire, Stefan Schreiber, William J Sandborn, et al.
Pageof 24